Condition: Gram Negative Infections · Antimicrobial Resistance (AMR) · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
A multicenter international prospective observational pharmacological study in adult patients (≥18 years) treated with ceftazidime/avibactam (CAZ/AVI) alone or with CAZ/AVI plus fosfomycin (FOS) for infection due to carbapenem-resistant Enterobacterales (CRE) (KPC and/or OXA-48).
This description comes directly from the study's public registry record.
Maddalena Giannella, MD PhD · +390512143199 · maddalena.giannella@unibo.it
Always discuss trial participation with your own doctor first.
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna, Bologna, Italy | Recruiting |
| Instituto de Biomedicina de Sevilla (IBiS), Hospital Virgen Macarena/CSIC/Universidad de Sevilla | Seville, Seville, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06717594